Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

Inclusion Criteria:

1. Male or female patients aged 18 years or older with a physician's confirmeddiagnosis of severe eosinophilic, uncontrolled asthma.

2. Severe uncontrolled eosinophilic asthma requiring high-dose* inhaled corticosteroidplus long-acting β adrenoceptor agonist as maintenance treatment.

3. Patients who have been prescribed but not yet initiated treatment with benralizumab (Fasenra®) according to local approved prescribing information prior to signedinformed consent.

4. Provision of the signed written informed consent form (ICF) indicating that theyunderstand the purpose of the study and procedures required for participation.

5. Patients must be able and willing to read and comprehend written instructions andcomplete the paper PRO questionnaires required by the protocol.

Exclusion Criteria:

1. Clinically important pulmonary diseases other than asthma including chronicobstructive pulmonary disease (as the main diagnosis), bronchiectasis, idiopathicpulmonary fibrosis, pulmonary hypertension, alpha-1-antitrypsin-deficiency, andmalignancy of any kind (NB: the following conditions are permitted: nasal polyposis,allergic rhinitis, atopic dermatitis, non-idiopathic pulmonary fibrosis).

2. Currently enrolled in an interventional clinical study except patients being inparallel documented in a national asthma registry

3. An acute or chronic condition that, in the investigator's opinion, would limit thepatients' ability to complete questionnaires or participate in this study or impactthe interpretations of results.

4. Concurrent biologics for asthma are not allowed. Acceptable wash-out periods forother asthma biologics: ≥30 days from the last dose of the previous biologic.

5. Women who are currently pregnant, breastfeeding, or lactating